"Designing Growth Strategies is in our DNA"

U.S. CAR-T Cell Therapy Market Size, Share & Industry Analysis, By Drug (Yescarta, Tecartus, Carvykti, Abecma, Breyanzi, Kymriah, and Others), By Indication (Acute Lymphoblastic Leukemia (ALL), Non-Hodgkin Lymphoma (NHL), and Multiple Myeloma), By End-user (Hospitals and Oncology Treatment Centers), and Country Forecast, 2024-2032

Last Updated: November 17, 2025 | Format: PDF | Report ID: FBI109015

 

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Prevalence of Chronic Diseases, U.S., 2023
    2. Pipeline Analysis, By Key Players
    3. Technological Advancements in CAR-T Cell Therapy
    4. New Product Launches, By Key Players
    5. Recent Industry Developments – Mergers, Acquisitions & Partnerships
    6. Impact of COVID-19 on the Market
  5. U.S. CAR-T Cell Therapy Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Drug
      1. Yescarta
      2. Tecartus
      3. Carvykti
      4. Abecma
      5. Breyanzi
      6. Kymriah
      7. Others
    2. Market Analysis, Insights and Forecast – By Indication
      1. Acute Lymphoblastic Leukemia (ALL)
      2. Non-Hodgkin Lymphoma (NHL)
      3. Multiple Myeloma
    3. Market Analysis, Insights and Forecast – By End-User
      1. Hospitals
      2. Oncology Treatment Centers
  6. Competitive Analysis
    1. U.S. Market Share Analysis (2023)
    2. Company Profiles
      1. Bristol-Myers Squibb Company
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      2. Ferring B.V.
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      3. Johnson & Johnson Services, Inc.
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      4. Novartis AG
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      5. Spark Therapeutics, Inc.
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      6. Enzyvant Therapeutics GmbH
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      7. bluebird bio, Inc.
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      8. Gilead Sciences, Inc.
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      9. CARsgen Therapeutics Holdings Limited
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Prevalence of Chronic Diseases, U.S., 2023
    2. Pipeline Analysis, By Key Players
    3. Technological Advancements in CAR-T Cell Therapy
    4. New Product Launches, By Key Players
    5. Recent Industry Developments – Mergers, Acquisitions & Partnerships
    6. Impact of COVID-19 on the Market
  5. U.S. CAR-T Cell Therapy Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Drug
      1. Yescarta
      2. Tecartus
      3. Carvykti
      4. Abecma
      5. Breyanzi
      6. Kymriah
      7. Others
    2. Market Analysis, Insights and Forecast – By Indication
      1. Acute Lymphoblastic Leukemia (ALL)
      2. Non-Hodgkin Lymphoma (NHL)
      3. Multiple Myeloma
    3. Market Analysis, Insights and Forecast – By End-User
      1. Hospitals
      2. Oncology Treatment Centers
  6. Competitive Analysis
    1. U.S. Market Share Analysis (2023)
    2. Company Profiles
      1. Bristol-Myers Squibb Company
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      2. Ferring B.V.
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      3. Johnson & Johnson Services, Inc.
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      4. Novartis AG
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      5. Spark Therapeutics, Inc.
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      6. Enzyvant Therapeutics GmbH
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      7. bluebird bio, Inc.
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      8. Gilead Sciences, Inc.
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
      9. CARsgen Therapeutics Holdings Limited
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. financials (Based on Availability)
Read Less

Figure 1: U.S. CAR-T Cell Therapy Market Revenue Breakdown (USD billion, %) by Drug Type, 2023 & 2032

Figure 2: U.S. CAR-T Cell Therapy Market Value Share (%), by Drug Type, 2023 & 2032

Figure 3: U.S. CAR-T Cell Therapy Market Value Share (%), by Indication, 2023 & 2032

Figure 4: U.S. CAR-T Cell Therapy Market Value Share (%), by End-User, 2023 & 2032

Figure 5: U.S. CAR-T Cell Therapy Market Share (%), By Company, 2023

Table 1: U.S. CAR-T Cell Therapy Market Revenue (USD billion) Forecast, by Drug Type, 2019–2032

Table 2: U.S. CAR-T Cell Therapy Market Revenue (USD billion) Forecast, by Indication, 2019–2032

Table 3: U.S. CAR-T Cell Therapy Market Revenue (USD billion) Forecast, by End-User, 2019–2032

U.S. CAR-T Cell Therapy Market
  • 2019-2032
  • 2023
  • 2019-2022
  • 70
Download Free Sample

    man icon
    Mail icon
    Captcha refresh
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann

Related Reports